Wei Zhou, Ph.D.
Guangdong University of Technology
No. 100 Waihuan Xi Road, Higher Education Mega Center, Guangzhou RP China, 510530
E-mail: zhou_wei@gdut.edu.cn
Phone: (+86)15989141979
Fax: (+86)20 32015232
Work Experience
LecturerGuangdong University of Technology Oct. 2015 to Now
School of Biomedical and Pharmaceutical Sciences
Research assistantChinese Academy of Sciences July 2014 to Aug. 2015
Institute of Chemical Biology, Guangzhou Institutes of Biomedicine and Health
EDUCATION
Doctor of Philosophy-Medicinal Chemistry Jun 2014
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
·Research Advisor: Prof. Wenhui Hu
·Proposed dissertation: The design, synthesis and biological evaluation of neuroinflammation inhibitors for Alzheimer’s disease
Bachelor of Medical Science- Pharmaceutical Science Jun 2009
Ocean University of China
RESEARCH EXPERIENCE
Neuroinflammation inhibitors for anti-Alzheimer drug developmentSep 2010-Aug 2015
·Skilled instructuraloptimization to improve biological activity and synthesis route design of target compounds
·Familiar with strategies to improve pharmacokinetic properties of CNS bio-active compounds
·Mastered skills of synthetic process monitoring and compound identification, such as GC/LC-MS, NMR and IR
Chemical Probes for mechanism-of-actionstudyJun 2011-Dec 2011
·Familiar with chemical probes design and synthesis, and the mechanism to explore direct binding proteins using the method of activity-based protein profiling (ABPP)
·Participated in the design and synthesis of several chemical probes searching for unknown protein targets of an active compound identified through phenotypic screenings
Theimprovement for synthesis of the anti-cancer drug vandetanibMar 2012-Aug 2012
·Participated in the improvement for synthesis of the anti-cancer drug vandetanib, 15% yield in 6 steps
·Had experience in multi-step synthesis on hectogram scale
Neuroinflammation inhibitors for anti-stroke drug developmentSep 2010-present
·Participated in the development of compound 189 for ischemic stroke which had been inphase I clinical trial;
GRANTS
·Pharmacokinetic-driven structural optimization of a neuroinflammatory inhibitor and therapeutic potential in an Alzheimer’s animal model, supported by Natural Science Foundation of China (81502911)
·Study ofGLUT-1-aided BBB penetration of anti-tumor lead optimization, supported by Municipal Science and Technology Programs of Guangzhou (202002030212)
·Identification and Optimization of Natural derived RAGE inhibitors and anti-neuroinflammatory Activity Study, supported by Young Innovative Talent Programs of Guangdong Province (2015KQNCX032)
PARTICIPATE IN RESEARCH PROJECTS
·Hit-to-lead optimization of a neuroinflammation inhibitor for treatment of Alzheimer’s disease, supported by Natural Science Foundation of Guangdong Province (10251066302000000)
·Pre-clinical study of a pyridazine-3-carboxamide derivative as a novel anti-neuroinflammatory agent for therapeutic treatment of Alzheimer’s disease, supported by Major Science and Technology Program of Guangdong Province (2012A080201013)
RESEARCH INTERESTS
Development of therapeutic, preventive, or diagnostic small chemical molecules forCNS-related diseases, such as Alzheimer’s disease, Parkinson’s disease and ischemic stroke. Multi-disciplinary collaboration that involves organic synthesis, neuropharmacology, pharmacokinetics,toxicologyandso on.Design and synthesis of activity-based chemical probes for mechanism-of-action studies.
RESEARCH COLLABORATIONS
McKeating group, University of Birmingham, September 2013
·Exploration of new anti-inflammatory agents for treating different liver diseases
Wattersongroup, Northwestern University, summer 2012
·Developmentof anti-neuroinflammatory agents with therapeutic potential for traumatic brain injury and ischemic stroke
PUBLICATIONS
lWei Zhou, Mengmeng Hu, Xiaohao Zang, Qifa Liu, Jiantang Du, Jingrong Hu, Lanyue Zhang, Zhiyun Du, Zhangmin Xiang*,Luteolin attenuates imiquimod–induced psoriasis-like skin lesions in BALB/c mice via suppression of inflammation response,Biomedicine & Pharmacotherapy131 (2020) 110696
lWei Zhou,Wenjin Zhang, Yi Peng, Zhi-Hong Jiang, Lanyue Zhang and Zhiyun Du, Design, Synthesis and Anti-Tumor Activity of Novel Benzimidazole-Chalcone Hybrids as Non-Intercalative Topoisomerase II Catalytic Inhibitors,Molecules2020, 25, 3180; doi:10.3390/molecules25143180
lWei Zhou*, Qingwei Xiao, Yuanyuan Chang, Qifa Liu, Xiaohao Zang, Mengmeng Hu, Xi Zeng, Zhiyun Du and Guifa Zhong, Substrate-controlled Diastereoselective Michael Addition of Alkylidene Malonates by Grignard Reagents,Heterocyclic Communications. 2019; 25: 116–121,
lPing Sun,§Wei Zhou,§ Hu Yue, Cheng Zhang, Yitao Ou, Zhongjin Yang,* and Wenhui Hu*,Compound AD110 Acts as Therapeutic Management for Alzheimer’s Disease and Stroke in Mouse and Rat Models,ACS Chemical Neuroscience2020, 11, 929−938,https://dx.doi.org/ 10.1021/acschemneuro.9b00651
lWei Zhou, Qifa Liu, Xiaohao Zang, Mengmeng Hu, Yuan Yue, Yuchu Wang, Chunyan Lv2, Zhiyun Du, Combination use of tolfenamic acid with curcumin improves anti-inflammatory activity and reduces toxicity in mice,Journal Food Biochemistry, 2020, 00, e13240, https://doi.org/10.1111/jfbc.13240
lWei Zhou, Guifa Zhong, Wenhui Huetal,.Microglia-Based Phenotypic Screening Identifies a Novel Inhibitor of Neuroinflammation Effective in Alzheimer Mouse Model.ACS Chemical Neuroscience2016, 7, 1499−1507.
lWei Zhou, Guifa Zhong, Xiurong Rao, Hui Xie, Shaogao Zeng, Tianyan Chi, Libo Zou, Donghai Wu, and Wenhui Hu, Identification of aminopyridazine-derived antineuroinflammatory agents effective in an Alzheimer's mouse model.ACS Medicinal Chemistry Letters3, 903-907 (2012);
lWei Zhou& Wenhui Hu, Anti-neuroinflammatory agents for the treatment of Alzheimer’s disease.Future Medicinal Chemistry5, 1559-1571 (2013);
lWei Zhou& Wenhui Hu, The development of anti-neuroinflammatory agents for the treatment of Alzheimer’s disease.Chinese Science Bulletin59(3),232-237(2014) ;
lKazsoki, A.; Fejős, I.; Sohajda, T.;Zhou, W.; Hu, W.; Szente, L.; Béni, S., Development and validation of a cyclodextrin‐modified capillary electrophoresis method for the enantiomeric separation of vildagliptin enantiomers.Electrophoresis2016,37(10), 1318-1325;
lYue, Y.; Liu, W.;Zhou, W.; Chen, M.; Huang, B.; Zhang, L.; Wang, Z.; He, Y.; Zhang, K.; Zheng, X.; Du, Z., Synergistic inhibitory effects of naproxen in combination with magnolol on TPA-induced skin inflammation in mice.RSC Advances2016,6(44), 38092-38099
lIda Feös, Zsuzsanna Urbancsok,Wei Zhou, Tamás Sohajda, Wenhui Hu, Lajos Szente, Szabolcs Béni, Separation of alogliptin enantiomers in cyclodextrin-modified capillary electrophoresis: a validated method.Electrophoresis35 (19), 2885-2891 (2014)
l胡蒙蒙,刘起发,臧小豪,胡锦荣,杜健堂,周渭*吴茱萸次碱抑制脂多糖诱导的BV2小胶质细胞炎症反应并改善神经 炎症模型小鼠学习记忆功能损伤中华中医药学报,2020
NEXT:Zhou Li-Hua